» Articles » PMID: 23124877

Flt3 Ligand Expands CD4+ FoxP3+ Regulatory T Cells in Human Subjects

Overview
Journal Eur J Immunol
Date 2012 Nov 6
PMID 23124877
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

CD4(+) CD25(+) FoxP3(+) naturally occurring regulatory T (Treg) cells play a crucial role in the maintenance of immune tolerance and in preventing autoimmune pathology. Interventions that expand Treg cells are highly desirable, as they may offer novel treatment options in a variety of autoimmune and transplantation settings. Paralleling previous preclinical studies, we demonstrate here that administration of the hematopoietic growth factor Flt3L to human subjects increases the frequency and absolute number of Treg cells, and reduces the ratio of CD8(+) T cells to Treg cells in the peripheral blood. The increase in Treg cells was due to enhanced Treg-cell proliferation rather than release of Treg cells from the thymus. Further studies revealed that Flt3L-induced proliferation of Treg cells was an indirect effect that occurred via the interaction of Treg cells with the Flt3L-expanded pool of CD1c(+) myeloid dendritic cells. On the basis of these findings, Flt3L may represent a promising agent for promoting immune tolerance in a variety of clinical settings.

Citing Articles

Cross-priming in cancer immunology and immunotherapy.

Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A Nat Rev Cancer. 2025; .

PMID: 39881005 DOI: 10.1038/s41568-024-00785-5.


XCL1-secreting CEA CAR-T cells enhance endogenous CD8 T cell responses to tumor neoantigens to confer a long-term antitumor immunity.

Li X, Wang F, Chen K, Wu Z, Zhang R, Xiao C J Immunother Cancer. 2025; 13(1.

PMID: 39762074 PMC: 11749649. DOI: 10.1136/jitc-2024-010581.


Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity.

Hu M, Fan D, Tu H, Tsai Y, He L, Zhou Z Gene Ther. 2024; .

PMID: 39472678 DOI: 10.1038/s41434-024-00497-3.


Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.

Boopathy A, Nekkalapudi A, Sung J, Schulha S, Jin D, Sharma B J Virol. 2024; 98(7):e0029424.

PMID: 38829139 PMC: 11265421. DOI: 10.1128/jvi.00294-24.


A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.

Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Martinez Janez N Cancer Med. 2024; 13(5).

PMID: 38501219 PMC: 10949085. DOI: 10.1002/cam4.6776.